Yongin Severance Hospital
Welcome,         Profile    Billing    Logout  
 11 Trials 
17 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Joo Sung
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Recruiting
2
40
US, RoW
ABN401
Abion Inc
Advanced Solid Tumors
04/25
08/25
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Recruiting
N/A
9
RoW
ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell
Anterogen Co., Ltd.
Crohn Disease
12/26
12/26
Harper, Amy
NCT04800874 / 2024-000202-16: Study of BBP-418 in Patients With LGMD2I

Active, not recruiting
2
14
US
BBP-418
ML Bio Solutions, Inc., ML Bio Solutions
LGMD2I
11/26
11/26
NCT05693142: AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting
1/2
15
US
RGX-202
REGENXBIO Inc.
Duchenne Muscular Dystrophy
12/25
12/25
DELIVER, NCT05524883 / 2021-005478-24: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Recruiting
1/2
88
Europe, Canada, US, RoW
DYNE-251, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Duchenne Muscular Dystrophy (DMD)
11/29
11/29
NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting
N/A
700
Europe, Japan, US, RoW
Prospective observational registry, Zolgensma
Novartis Pharmaceuticals, United BioSource, LLC
Spinal Muscular Atrophy (SMA)
06/38
06/38
Lee, Si Hyung
PICASA, NCT04616092: Effect of Preoperative Intravenous Ferric Carboxymaltose for Clipping Surgery

Not yet recruiting
4
130
NA
FEFINJECT
Seoul National University Hospital, Vifor Pharma
Cerebral Aneurysm Unruptured, Iron Deficiency Anemia, Surgery
11/22
04/23
NCT05801146: Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

Recruiting
3
272
RoW
Botulinum Toxin Type A Injection [HG102], HG102, Botulinum Toxin Type A Injection [Botox], Botox®
Hugel
Glabellar Lines
03/25
10/25
Kim, Na Young
NCT06665412: Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

Recruiting
N/A
168
RoW
Radotinib Hydrochloride
Il-Yang Pharm. Co., Ltd.
Chronic Phase Ph+ Chronic Myeloid Leukemia
09/26
12/26
Kim, Yongcheol
C-STAR, NCT05661552: Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Active, not recruiting
4
108
RoW
Evolocumab 140 MG/ML, REPATHA® (Amgen Inc, Thousand Oaks, California, USA), Rosuvastatin 5mg, Ezetimibe 10mg
Yonsei University, Daewoong Pharmaceutical Co. LTD.
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
03/25
11/25
SEVEN-BOX, NCT05006027: Feasibility of PCI Using a 7-Fr Thin-Walled Sheath Via the DRA

Active, not recruiting
N/A
100
RoW
Percutaneous coronary intervention via the distal radial approach
Yonsei University, Severance Hospital, Merit Medical Systems, Inc.
Coronary Artery Disease, Distal Radial Artery, Complex Intervention
07/24
10/24
ONYSOVER, NCT05340361: Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT

Recruiting
N/A
30
RoW
Optical coherence tomography-guided percutaneous coronary intervention, Zotarolimus-eluting stent (Onyx family stent, Medtronic, Santa Rosa, CA, USA), Optical coherence tomography-guided Onyx family stent expansion
Yonsei University, Severance Hospital, Medtronic
Coronary Artery Disease, Optical Coherence Tomography, Stent
12/25
12/25
ROAD-IFR, NCT05682118: Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve

Recruiting
N/A
226
RoW
roadmap, iFR/FFR
Yonsei University, Philips Healthcare
Ischemic Heart Disease
11/25
11/25
ICE-HEAT, NCT05421169: Diastolic Hyperemia-Free Ratio in Patients With CAD

Completed
N/A
300
RoW
diastolic hyperemia-free ratio (DFR)
Yonsei University, Severance Hospital, Boston Scientific Corporation
Coronary Stenosis, Coronary Artery Disease
02/24
03/24
NCT05448625: Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)

Recruiting
N/A
200
RoW
Genoss DES
Yonsei University, Severance Hospital, Genoss Co., Ltd.
Drug-eluting Stent, Coronary Artery Disease
12/24
12/26
Roh, Jiwoong
No trials found
Kim, Jinkwon
No trials found
Kim, Jongchan
No trials found
BYUN, Hwakyung
No trials found
Kim, Woojung
No trials found

Download Options